Independence Blue Cross began limiting coverage of GLP-1 drugs on Jan. 1 to some medical conditions, but not obesity or weight loss.

For years, people taking Ozempic or other drugs in the same class for diabetes and weight loss have noticed the medicines don ...

People taking weight-loss drugs say they are losing their sight. Science is trying to figure out why - There’s no direct link ...

There are no studies documenting the percentage of doctors taking the drugs. But physicians “are a good litmus test for drugs ...

WVU Medicine is playing a lead role in a national clinical study of a minimally invasive surgical procedure for people who've ...

Eli Lilly reported mixed results for the fourth quarter, even as demand for its blockbuster weight loss drug Zepbound and ...

Eli Lilly is set to report fourth-quarter earnings early Thursday, with analysts expecting rising sales and profit in the first full quarter with the company's weight-loss drugs no longer in shortage.

Taking a compounded GLP-1 medication isn’t the same thing as your pharmacy filling a cheaper, generic version of the drug ...

The results of the first head-to-head trial of Lilly's dual GLP-1/GIP agonist Zepbound (tirzepatide ... tirzepatide achieved at least 25% body weight loss compared to 16.1% of those receiving ...

More U.S. adults believe it is a good thing than a bad thing for adults to use weight-loss drugs like Ozempic, Wegovy and other brands if they are struggling with obesity or have a health ...

The media mogul's weight loss first caught the public's attention when she walked the red carpet at the premiere for the remake of “The Color Purple” in December 2023. The same month ...

Zepbound is ... effectiveness. A 6-month study of Rybelsus found an average drop of 1 to 1.3% A1C in adults with a starting A1C of 8.3%. While Rybelsus is not a weight loss medication, the ...